Stocks Health care COCH
NASDAQ · Health careEnvoy Medical, Inc. (COCH)
Envoy Medical, Inc. brought in $207K of revenue over the twelve months to June 30, 2026, down 6.8% from a year earlier. It posted a net loss of $23.4M. In fiscal 2025 capital spending exceeded operating cash flow by $18.4M. At June 30, 2026 it held $19.7M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 10, 2026.
Key facts about Envoy Medical, Inc.
- Net worth
- Envoy Medical, Inc. has a market value (market cap) of $548.1M at the latest share price, and shareholders' equity of $3.3M on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Revenue and profit
- In fiscal 2025 revenue was $241K (+7.1% year on year), with a net loss of $23.8M. Over the 12 months to June 30, 2026: revenue $207K, net loss $23.4M.
- Cash flow
- In fiscal 2025 operations used $18.2M of cash.
- Latest report
- The latest periodic report (quarterly report, 10-Q) was filed with the SEC on August 10, 2026 and covers the period to June 30, 2026. Open on SEC EDGAR
- Next earnings report
- Envoy Medical, Inc.'s next report was expected around November 9, 2026 and is not on file with the SEC yet.
What Envoy Medical, Inc. does
Envoy Medical, Inc. is registered with the SEC under industry code SIC 3842 (Orthopedic, Prosthetic & Surgical Appliances & Supplies). Its shares trade on NASDAQ under the ticker COCH.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $241K | -$23.8M | -$1.23 | -$18.4M |
| 2024 | $225K | -$20.8M | -$1.49 | -$18.9M |
| 2023 | $316K | -$29.9M | -$2.54 | -$17.2M |
| 2022 | $237K | -$15.9M | -$1.68 | -$9M |
| 2021 | n/a | -$251.6K | n/a | n/a |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Where COCH ranks in Health care
Dividends
It paid out $1.8M in cash dividends.
| Fiscal year | Per share | Paid out | Of profit |
|---|---|---|---|
| 2025 | n/a | $1.8M | n/a |
| 2024 | n/a | $2.4M | n/a |
Latest SEC filings
What Envoy Medical, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- September 14, 2026Passive stake changed SCHEDULE 13G/A
- September 2, 2026Additional proxy material DEFA14A
- August 31, 2026Proxy statement DEF 14A
- August 27, 2026
- August 19, 2026Preliminary proxy statement PRE 14A
- August 10, 2026
- August 10, 2026Quarterly report 10-Q · period to June 30, 2026Revenue fell 35% to $51K versus the same quarter last year; diluted EPS -$0.07 versus -$0.32.
- June 30, 2026
- June 25, 2026
- June 12, 2026Form POS AM filing POS AM
Insider trades
What the people running Envoy Medical, Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.
No insider trades were reported in the last 90 days.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| May 29, 2026 | Lucas Brent T.Chief Executive Officer, Director | Received as pay | 32,856 | $19.7K |
| February 12, 2026 | Lucas Brent T.Chief Executive Officer, Director | Bought | 62,500 | $25K |
| February 12, 2026 | Brynelsen CharlesDirector | Bought | 1,000,000 | $400K |
| February 12, 2026 | Kantor SusanDirector | Bought | 96,150 | $38.5K |
| February 12, 2026 | Potashnick RobertInterim CFO | Bought | 212,500 | $85K |
| February 12, 2026 | Patel Mona ChetanDirector | Bought | 312,500 | $125K |
| February 12, 2026 | Taylor Glen A10% owner | Bought | 18,750,000 | $7.5M |
| November 28, 2025 | Lucas Brent T.Chief Executive Officer, Director | Received as pay | 18,105 | $12.9K |
Who owns COCH
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| Glen A. Taylor13D, may seek influence | 84.8% | February 17, 2026 |
| Anzu SPAC GP I LLC13D, may seek influence with 3 related filers | 11.33% | December 26, 2024 |
| Bleichroeder LP13G, passive with 2 related filers | 9.99% | May 14, 2026 |
| Nantahala Capital Management, LLC13G, passive with 2 related filers | 9.99% | May 15, 2026 |
Largest institutional holders
Positions that investment managers reported on Form 13F for the quarter ended June 30, 2026, largest first, with the change on the quarter ended March 31, 2026. Managers file 13F up to 45 days after a quarter ends. 62 managers reported a position.
| Holder | Shares | Change on quarter |
|---|---|---|
| Nantahala Capital Management, LLC | 15,300,000 | +7,650,000 |
| Bleichroeder LP | 6,250,000 | 0 |
| Vanguard Capital Management LLC | 880,214 | -1,458 |
| DSG Capital Advisors, LLC | 625,000 | 0 |
| Geode Capital Management, LLC | 541,729 | +19,905 |
| Focus Partners Wealth | 425,310 | +212,655 |
| Vanguard Fiduciary Trust Co | 296,679 | +1,958 |
| UBS Group AG | 190,838 | +120,379 |
| Arcus Capital Partners, LLC | 187,573 | 0 |
| ExodusPoint Capital Management, LP | 182,354 | new |
| Northern Trust Corp | 109,466 | -1,584 |
| Oasis Management Co Ltd. | 100,000 | 0 |
| Morgan Stanley | 90,921 | +17,021 |
| CIBC Bancorp USA Inc. | 77,887 | 0 |
| Aristeia Capital, L.L.C. | 1,143,978 | 0 |
| LPL Financial LLC | 48,401 | +20,000 |
| Jane Street Group, LLC | 239,389 | +31,223 |
| Toronto Dominion Bank | 534,600 | -128 |
| Meteora Capital, LLC | 28,051 | 0 |
| State Street Corp | 23,872 | 0 |
Insiders
6 insiders reported holding 23,802,590 shares in total, about $169M at the last price.
| Holder | Shares |
|---|---|
| Taylor Glen A10% owner | 21,703,607 |
| Brynelsen CharlesDirector | 1,050,000 |
| Patel Mona ChetanDirector | 332,500 |
| Lucas Brent T.Chief Executive Officer, Director | 329,946 |
| Potashnick RobertInterim CFO | 212,500 |
| Kantor SusanDirector | 174,037 |
Questions about COCH
What does Envoy Medical, Inc. do?
Envoy Medical, Inc. is a company in the Health care sector, listed on NASDAQ as COCH. Its shares trade on NASDAQ under the ticker COCH.
What is Envoy Medical, Inc.'s net worth?
Envoy Medical, Inc. has a market value (market cap) of $548.1M at the latest share price, and shareholders' equity of $3.3M on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is Envoy Medical, Inc. profitable?
No. Over the twelve months to June 30, 2026 it reported a net loss of $23.4M on revenue of $207K.
How much revenue does Envoy Medical, Inc. make?
Over the twelve months to June 30, 2026 Envoy Medical, Inc. reported revenue of $207K. That is 6.8% less than a year earlier.
When did Envoy Medical, Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on August 10, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the passive stake changed from September 14, 2026.
When is Envoy Medical, Inc.'s next earnings report?
Envoy Medical, Inc.'s next report was expected around November 9, 2026 and is not on file with the SEC yet.
Similar companies
Compare COCH with
Follow COCH
Get an email when Envoy Medical, Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values Envoy Medical, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.